Patents by Inventor Richard Alexander Jelley

Richard Alexander Jelley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclohexyl sulphones as gamma-secretase inhibitors
    Patent number: 7410964
    Abstract: Compounds of formula I: inhibit gamma-secretase and hence find use in treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: August 12, 2008
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Kevin Dinnell, Karl Richard Gibson, Timothy Harrison, Richard Alexander Jelley, Alan John Nadin, Paul Joseph Oakley, Andrew Pate Owens, Duncan Edward Shaw, Brian John Williams
  • Tetrahydropyran compounds as tachykinin antagonists
    Patent number: 7393858
    Abstract: The present invention relates to compounds of formula (Ia) wherein A, B, n, m, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are defined herein, and pharmaceutically acceptable salts thereof; the compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.
    Type: Grant
    Filed: March 4, 2004
    Date of Patent: July 1, 2008
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Olivier Dirat, Jason Matthew Elliott, Ian Thomas Huscroft, Richard Alexander Jelley, Janusz Jozef Kulagowski, Piotr Antoni Raubo, Duncan Edward Shaw, Francine Sternfeld, Christopher John Swain
  • Imidazolophthalazine derivatives as ligands for GABAA receptors
    Patent number: 6949549
    Abstract: A class of substituted imidazolo[5,1-a]phthalazine derivatives as ligands for GABAA receptors of formula I which are partial or full inverse agonists of an ?5 receptor subunit while being relatively free of activity at ?1 and/or ?2 and/or ?3 receptor subunit binding sites are described herein; they are therefore of benefit as a medicament for enhancing cognition but with the reduction or elimination of proconvulsant activity.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: September 27, 2005
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Richard Alexander Jelley, Tamara Ladduwahetty, Angus Murray MacLeod, Andrew Madin, Francine Sternfeld
  • Imidazolophthalazine derivatives as ligands for gabaa receptors
    Publication number: 20040147517
    Abstract: A class of substituted imidazolo[5,1-a]phthalazine derivatives as ligands for GABAA receptors which are partial or full inverse agonists of an &agr;5 receptor subunit while being relatively free of activity at &agr;1 and/or &agr;2 and/or &agr;3 receptor subunit binding sites; they are therefore of benefit as a medicament for enhancing cognition but with the reduction or elimination of procon-vulsant activity.
    Type: Application
    Filed: January 16, 2003
    Publication date: July 29, 2004
    Inventors: Richard Alexander Jelley, Tamara Ladduwahetty, Angus Murray MacLeod, Andrew Madin, Francine Sternfeld
  • Substituted 1-indolylpropyl-4-phenethylpiperazadine derivatives
    Patent number: 5889008
    Abstract: A class of 1-?3-(1H-indol-3-yl)propyl!-4-(2-phenylethyl) piperazine derivatives, substituted at the 5-position of the indole nucleus by a five-membered heteroaromatic moiety, and on the phenyl ring of the phenethyl moiety by fluoro, chloro, trifluoromethyl, alkoxy or an oxazolidinone group and optionally by one or two further substituents, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D .alpha. receptor subtype while possessing at least a 10-fold selective affinity for the 5-HT.sub.1D .alpha. receptor subtype relative to the 5-HT.sub.1D .alpha. subtype; they are therefore usefull in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, while eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.
    Type: Grant
    Filed: February 5, 1998
    Date of Patent: March 30, 1999
    Assignee: Merck Sharp & Dohme, Ltd.
    Inventors: Richard Alexander Jelley, Angus Murray MacLeod, Austin John Reeve, Francine Sternfeld, Leslie Joseph Street
  • Azetidine, pyrrolidine and piperidine derivatives
    Patent number: 5854268
    Abstract: A class of substituted azetidine, pyrrolidine and piperidine derivatives are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.
    Type: Grant
    Filed: January 22, 1997
    Date of Patent: December 29, 1998
    Assignee: Merck Sharp & Dohme, Ltd.
    Inventors: Raymond Baker, Sylvie Bourrain, Jose Luis Castro Pineiro, Mark Stuart Chambers, Alexander Richard Guiblin, Sarah Christine Hobbs, Richard Alexander Jelley, Andrew Madin, Victor Giulio Matassa, Austin John Reeve, Michael Geoffrey Russell, Graham Andrew Showell, Francine Sternfeld, Leslie Joseph Street, Monique Bodil Van Niel